Literature DB >> 15145472

Neurocognition and long-term prediction of quality of life in outpatients with severe and persistent mental illness.

Daryl E Fujii1, A Michael Wylie, Jeffrey H Nathan.   

Abstract

The present study examined the predictive validity of neuropsychological measures to quality of life (QOL) indicators in 30 outpatients with severe and persistent mental illness (SPMI), an average of 15 years post-testing. Outcome measures included subscale scores on the Brief Quality of Life Inventory (BQOLI). Results of several stepwise multiple regressions revealed that memory was predictive of income, satisfaction with daily activities, and general health. Executive functioning was predictive of contact with family and financial support. Motor skills were predictive of satisfaction with family contact, and working memory was predictive of victimization and satisfaction with social contacts. Discussion focused on neurocognition as a predictor of QOL, clinical implications, and the potential for improving QOL through cognitive interventions. Copyright 2003 Elsevier B.V.

Entities:  

Mesh:

Year:  2004        PMID: 15145472     DOI: 10.1016/S0920-9964(03)00122-1

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  15 in total

1.  The RSM-scale: a pilot study on a new specific scale for self- and observer-rated quality of life in patients with schizophrenia.

Authors:  M Riedel; I Spellmann; R Schennach-Wolff; M Obermeier; R Musil
Journal:  Qual Life Res       Date:  2010-10-05       Impact factor: 4.147

Review 2.  Psychomotor slowing in schizophrenia.

Authors:  Manuel Morrens; Wouter Hulstijn; Bernard Sabbe
Journal:  Schizophr Bull       Date:  2006-11-08       Impact factor: 9.306

Review 3.  Cognition, function, and disability in patients with schizophrenia: a review of longitudinal studies.

Authors:  Tarek K Rajji; Dielle Miranda; Benoit H Mulsant
Journal:  Can J Psychiatry       Date:  2014-01       Impact factor: 4.356

4.  D-Serine and a glycine transporter-1 inhibitor enhance social memory in rats.

Authors:  Toshiharu Shimazaki; Ayaka Kaku; Shigeyuki Chaki
Journal:  Psychopharmacology (Berl)       Date:  2010-03-03       Impact factor: 4.530

5.  Association between the G1001C polymorphism in the GRIN1 gene promoter and schizophrenia in the Iranian population.

Authors:  Hamid Galehdari; Atefeh Pooryasin; Alimohammad Foroughmand; Setareh Daneshmand; Mostafa Saadat
Journal:  J Mol Neurosci       Date:  2008-09-16       Impact factor: 3.444

6.  Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.

Authors:  Michael Riedel; Ilja Spellmann; Martin Strassnig; Anette Douhet; Sandra Dehning; Markus Opgen-Rhein; Rosamaria Valdevit; Rolf R Engel; Nikolaus Kleindienst; Norbert Müller; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-07-14       Impact factor: 5.270

Review 7.  Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review.

Authors:  Roger Henriksson; Thomas Asklund; Hans Skovgaard Poulsen
Journal:  J Neurooncol       Date:  2011-04-06       Impact factor: 4.130

8.  Criminal victimisation in people with severe mental illness: a multi-site prevalence and incidence survey in the Netherlands.

Authors:  Astrid M Kamperman; Jens Henrichs; Stefan Bogaerts; Emmanuel M E H Lesaffre; André I Wierdsma; Razia R R Ghauharali; Wilma Swildens; Yolanda Nijssen; Mark van der Gaag; Jan R Theunissen; Philippe A Delespaul; Jaap van Weeghel; Jooske T van Busschbach; Hans Kroon; Linda A Teplin; Dike van de Mheen; Cornelis L Mulder
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

Review 9.  A history of health-related quality of life outcomes in psychiatry.

Authors:  Dennis A Revicki; Leah Kleinman; David Cella
Journal:  Dialogues Clin Neurosci       Date:  2014-06       Impact factor: 5.986

Review 10.  Neurobiology of cognitive remediation therapy for schizophrenia: a systematic review.

Authors:  Anders Lillevik Thorsen; Kyrre Johansson; Else-Marie Løberg
Journal:  Front Psychiatry       Date:  2014-08-15       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.